January 5, 2017 – Executive search firm Coulter Partners has placed Dr. Giles Campion as chief medical officer (CMO) of Albumedix. Dr. Campion brings with him more than 25 years of experience in drug development from both large pharma and biotech companies having worked in senior development positions in the U.S. as well as Europe.
Previously, he was senior vice president of research and development and CMO at Prosensa Holdings and then group vice president, neuromuscular franchise at Biomarin following the Prosensa acquisition. Before that, Dr. Campion held positions such as global head of clinical research and development at general electric healthcare and European head of exploratory clinical development at Novartis.
With experience across all therapeutic areas, most recently in orphan neuromuscular disorders, Dr. Campion has overseen global and regional filing and approvals of new products in cardiovascular disease diabetes, oncology, neurodegenerative disease and hormone deficiency. During his career he has overseen the development of over 40 therapeutics and diagnostic agents.
“Coulter Partners was asked to recruit a new CMO in addition to a clinical development director for Albumedix,” said managing partner Arnaldo De Lisio, who led the search. “As the company moves towards the development of an in-house pipeline of drugs by combining biologics with their own Albumin-based technology, a need arose for a skilled drug hunter and developer to play a leading role in the biologics selection and development process, and to make an impact in driving forward this exciting new stage in the company’s progress.”
“I am delighted to welcome Giles Campion to Albumedix and I thank the exceptional team at Coulter Partners for conducting such a successful search on our behalf,” said Peter Rosholm, Albumedix chief executive officer. “Giles’ depth of experience across multiple therapeutic indications, drug development track record and expertise in the filings of specialized pharmaceuticals, will be invaluable to us as we move our preclinical drug candidates towards the clinic.”
|Check out our latest upload from Coulter Partners|
The appointment marks the latest step in the company’s growth strategy as it works to advance breakthroughs in the use of albumin in the development of life-changing therapeutics.
Albumedix develops albumin-enabled therapeutics using its albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Using its products and technologies,
The company is advancing a pipeline of proprietary and partnered drug programs in clinic and the market together with pharmaceutical companies worldwide.
Coulter Partners is a board and senior level executive search boutique focused exclusively on global life sciences. From offices in the U.K., Europe and North America, the firm serves clients in the pharmaceuticals, biotechnology, medical devices, diagnostics, CRO and services sectors.
Chief Medical Officers
CMO is the title used by many organizations for the senior government official designated head of medical services, sometimes at the national level. The post is held by a physician who serves to advise and lead a team of medical experts on matters of public health importance.
According to recruiters, the role of the chief medical officer has evolved in recent years, and organizations, as in this case, are looking for leaders with broader skill sets.
“Today’s CMO needs to have professional experience gathered from different players in the drug development industry, since he or she needs to understand the objectives of the key players in the field,” said Marc Salzberg, CEO of Airway Therapeutics. “That is, academia/clinical practice, the pharma industry, regulatory authorities and third-party vendors such as contract research organizations in order to successfully cooperate with those partners.”
A number of executive search firms have placed CMOs in recent months. Here is a look at a few from the Hunt Scanlon Media archives:
- Strawn Arnold & Associates placed R. Alberto Avendano, M.D., to serve as CMO of Osiris Therapeutics, Inc. Dr. Avendano brings to Osiris expertise in medical education and communication, academic and industry clinical research, pharmacovigilance and regulatory affairs.
- Quick Leonard Kieffer recruited Thomas Tracy Jr. MD as CMO at Penn State Milton S. Hershey Medical Center in Hershey, PA. Managing partner Dr. Robert Kuramoto led the search. Dr. Tracy spent almost two decades with the Lifespan system and Brown University in Rhode Island.
- Witt/Kieffer placed Ghassan Jamaleddine, MD, as CMO of Alameda Health System (AHS). The search was led by consultant Steve Yamada and associate Sue LeGrand. Dr. Jamaleddine came to AHS from New York City Health + Hospital/ Kings County Hospital in Brooklyn, New York.
Contributed by Dale M. Zupsansky, Managing Editor, Hunt Scanlon Media